Abstract: BACKGROUND: The detrimental impact of fluid overload (FO) on intensive care unit (ICU) morbidity and mortality is well known. However, research to identify subgroups of patients particularly prone to fluid overload is scarce. The aim of this cohort study was to derive "FO phenotypes" in the critically ill by using machine learning techniques. METHODS: Retrospective single center study including adult intensive care patients with a length of stay of >/=3 days and sufficient data to compute FO. Data was analyzed by multivariable logistic regression, fast and frugal trees (FFT), classification decision trees (DT), and a random forest (RF) model. RESULTS: Out of 1772 included patients, 387 (21.8%) met the FO definition. The random forest model had the highest area under the curve (AUC) (0.84, 95% CI 0.79-0.86), followed by multivariable logistic regression (0.81, 95% CI 0.77-0.86), FFT (0.75, 95% CI 0.69-0.79) and DT (0.73, 95% CI 0.68-0.78) to predict FO. The most important predictors identified in all models were lactate and bicarbonate at admission and postsurgical ICU admission. Sepsis/septic shock was identified as a risk factor in the MV and RF analysis. CONCLUSION: The FO phenotypes consist of patients admitted after surgery or with sepsis/septic shock with high lactate and low bicarbonate.
Tags: (Martin Muller) has nothing to disclose., Abbott AG, Baar, Switzerland, Abbott Nutrition International, Baar, Switzerland, AG, Basel, Switzerland, Allschwil, Switzerland, Anandic Medical Systems,, and Nycomed, Zurich, Switzerland outside the submitted work. The, Astellas, Wallisellen, Switzerland, Astra Zeneca, Baar, Switzerland, B., Bard Medica S.A., Allschwil,, Baxter, Opfikon, Switzerland, Bern, Switzerland, Bracco, Lausanne, Switzerland, Braun Medical AG, Melsungen, Germany, Covidien, Munchenbuchsee,, CSEM AG, Zurich, Switzerland, CSL Behring,, Drager AG, Liebefeld, Switzerland, Edwards, Eli Lilly and Company, Vernier, Switzerland, Feuertalhalen, Switzerland, fluid overload, fluid resuscitation, Fresenius Kabi, Kriens, Switzerland, Getinge Group Maquet AG, Rastatt, Germany, Glaxo Smith Kline, Brentford, UK, Hamilton Medical AG, Bonaduz, Switzerland, intensive care, Kenta Biotech Ltd., Bern,, Lifesciences Services GmbH, Nyon, Switzerland, Maquet Critical Care AB, Solna, Sweden, Merck Sharp and Dohme AG, Lucerne, Switzerland, money was paid into departmental funds, Nestle, Vevey, Switzerland, no personal financial gain applied. M.M., Novartis, Basel, Switzerland, Omnicare Clinical Research, Pan Gas AG Healthcare, Dagmersellen, Switzerland, Pfizer, Zurich, Switzerland, Pharma, Zug, Switzerland, Pierre Fabre Pharma AG,, risk factors, Switzerland, Teleflex Medical GmbH, Belp, Switzerland.